Argenx reported late-stage Phase 3 top-line results for Vyvgart Hytrulo (subcutaneous efgartigimod alfa) in autoimmune myositis, with statistical significance in a combined study that included immune-mediated necrotizing myopathy. The company said the treatment improved outcomes measured by Total Improvement Score and showed benefits beginning around week four. While the myositis subtypes showed uneven results, the IMNM subgroup—described by the company as having no approved targeted therapies—drove investor optimism. Analyst notes framed the outcome as an expansion opportunity for the Vyvgart franchise. —